Results 61 to 70 of about 8,933 (160)
Results of prophylaxis of venous thromboembolism after orthopedic operations
Вестник хирургии имени И.И. Грекова, 2017 OBJECTIVE. The research compared efficacy and safety of application of dabigatran and rivaroxaban in prevention of venous thromboembolism after orthopedic operations. MATERIAL AND METHODS.
B. S. Sukovatykh +2 more
doaj +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.Abstract Two Phase 1 open‐label studies were conducted in otherwise healthy participants, with BMI classified as overweight/obesity, to assess the potential of lotiglipron (a glucagon‐like peptide‐1 receptor agonist) as precipitant for pharmacokinetic (PK) drug–drug interactions (DDIs) when co‐administered with substrates of cytochrome P450 (CYP) 3A ...
Carol Cronenberger +11 more
wiley +1 more source
Dabigatran pharmacokinetics (PK).
, 2019 PK of dabigatran etexilate administrated by one dose of 10 mg/kg intraperitoneal. Plasma dabigatran (p-dabigatran) were measured in two healthy rats at each time point (n = 14).
Jens Peter Goetze (316975) +9 more
core +1 more source
Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate [PDF]
, 2016 WOS: 000368568400013PubMed ID: 26798391Dabigatran etexilate is one of the new oral anticoagulants approved to reduce the risk of stroke in patients with atrial fibrillation (AF). A variety of bleeding complications with dabigatran have been reported, but
Kızılırmak, Filiz +5 more
core +1 more source
AAPS OpenObjective Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of DRV, coadministered with cobicistat (
Sandy Van Hemelryck +5 more
doaj +1 more source
Неврология, нейропсихиатрия, психосоматика, 2016 A Regional Expert Council meeting was held in Moscow on August 21, 2015 to consider different aspects of the efficiency and safety of using the first direct thrombin inhibitor dabigatran etexilate in real clinical practice.
A. V. Fonyakin
doaj +1 more source
Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption
Obesity Reviews, Volume 27, Issue 4, April 2026.ABSTRACT Obesity represents a significant threat to global public health, with an estimated 16% of adults worldwide (2022) being classified as people with obesity, with a body mass index of 30 or more. Bariatric surgery is regarded as the most effective treatment option for people with obesity, with the three main types of bariatric surgery being ...
Danielle Wigg +3 more
wiley +1 more source
Critical Care Innovations, 2020 INTRODUCTION: To estimate the incidence of thromboembolic recurrence in patients whose deep vein thrombosis (DVT) during the initial and long-term anticoagulation and after its termination was treated.
Sergyi Vasyliuk, Vitaliia Atamaniuk
doaj +1 more source
Environmental and Molecular Mutagenesis, Volume 67, Issue 3, March 2026.ABSTRACT Conducting S9‐mediated preincubations at slightly acid pHs (e.g., pH 5.0 to pH 6.5) has been reported to enhance the mutagenicity of small‐molecule nitrosamines in the Ames test. In this study, we have evaluated the effect of adjusting the preincubation mix used in the Enhanced Ames Test (EAT) from pH 7.4 to pH 6.0 and supplying the activation
Michelle E. Bishop +11 more
wiley +1 more source
Clinical Evaluation of Drug–Drug Interactions With Aficamten
Clinical and Translational Science, Volume 19, Issue 3, March 2026.ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in ...
Neha Maharao +11 more
wiley +1 more source